Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.
It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases.
It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 13, 25 | 0.01 Increased by +105.26% | -0.02 Increased by +162.50% |
| Nov 7, 24 | 0.10 Increased by +211.11% | 0.01 Increased by +900.00% |
| Aug 1, 24 | 0.01 Increased by +112.50% | 0.01 |
| May 2, 24 | -0.03 Increased by +83.33% | -0.14 Increased by +78.57% |
| Feb 15, 24 | -0.19 Decreased by -5.56% | -0.16 Decreased by -18.75% |
| Nov 2, 23 | -0.09 Decreased by -50.00% | -0.17 Increased by +47.06% |
| Aug 3, 23 | -0.08 Increased by +68.00% | -0.18 Increased by +55.56% |
| May 4, 23 | -0.18 Increased by +33.33% | -0.22 Increased by +18.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 59.87 M Increased by +32.76% | 1.43 M Increased by +105.32% | Increased by +2.39% Increased by +104.01% |
| Sep 30, 24 | 67.77 M Increased by +24.32% | 14.35 M Increased by +206.72% | Increased by +21.17% Increased by +185.84% |
| Jun 30, 24 | 57.19 M Increased by +37.83% | 722.00 K Increased by +106.28% | Increased by +1.26% Increased by +104.56% |
| Mar 31, 24 | 50.30 M Increased by +46.19% | -10.75 M Increased by +58.98% | Decreased by -21.37% Increased by +71.94% |
| Dec 31, 23 | 45.09 M Increased by +58.59% | -26.88 M Decreased by -3.18% | Decreased by -59.60% Increased by +34.94% |
| Sep 30, 23 | 54.52 M Decreased by -2.27% | -13.45 M Decreased by -49.59% | Decreased by -24.67% Decreased by -53.06% |
| Jun 30, 23 | 41.49 M Increased by +47.19% | -11.49 M Increased by +67.64% | Decreased by -27.70% Increased by +78.02% |
| Mar 31, 23 | 34.41 M Increased by +59.12% | -26.21 M Increased by +30.36% | Decreased by -76.16% Increased by +56.23% |